I now have comprehensive content from Robbins PBD covering all key molecular mechanisms of carcinogenesis. Let me compile the full, structured answer.
Molecular Basis of Carcinogenesis
Source: Robbins, Cotran & Kumar - Pathologic Basis of Disease (ISBN 9780443264528)
Core Principles
Nonlethal genetic damage lies at the heart of carcinogenesis. Mutations may be caused by:
- Environmental exposures (chemicals, radiation, viruses)
- Inherited germline mutations
- Spontaneous/random ("bad luck") events
- Endogenous agents (reactive oxygen species, oncometabolites)
Tumors are clonal - they arise from expansion of a single precursor cell that has incurred genetic damage. All cells in a tumor share the same founding mutations.
Four principal gene classes are targeted by cancer-causing mutations:
- Growth-promoting proto-oncogenes
- Growth-inhibiting tumor suppressor genes
- Apoptosis-regulating genes
- DNA repair genes
Mutations accumulate in a stepwise fashion over time. The first is the initiating mutation, which alone is not fully transforming - additional driver mutations must be acquired. Passenger mutations are collateral damage that do not contribute to the cancer phenotype.
Hallmarks of Cancer
All cancers acquire eight fundamental changes through genomic and epigenomic alterations, enabled by genomic instability and tumor-promoting inflammation:
Fig. 7.20 - The Hallmarks of Cancer (Modified from Hanahan & Weinberg, Cell, 2011)
Hallmark 1: Self-Sufficiency in Growth Signals - Oncogenes
Proto-oncogenes are normal cellular genes that, when mutated or overexpressed, become oncogenes encoding constitutively active oncoproteins that drive proliferation without external stimuli.
Oncogenic mutations are gain-of-function and therefore dominant - a single mutant allele suffices.
Normal Growth Signaling Cascade (co-opted by oncogenes):
- Growth factor binds receptor
- Receptor tyrosine kinase transiently activates
- Cytoplasmic signal transducers relay signal
- Transcription factors are activated in the nucleus
- Growth-promoting genes are expressed → cell division
Key Oncoproteins:
Growth Factors
- PDGF-β chain: overexpressed in astrocytomas (autocrine loop)
- FGF: overexpressed in stomach and bladder carcinomas
Growth Factor Receptors (Receptor Tyrosine Kinases)
- ERBB2 (HER2/NEU): amplified in ~25% of breast and ovarian carcinomas; therapeutic target for trastuzumab
- RET: point mutations in MEN2A/2B, papillary thyroid carcinoma
- FLT3: mutated in AML; constitutively activates JAK/STAT signaling
Signal Transducers (RAS/MAPK pathway)
- RAS: most commonly mutated oncogene in human tumors (~30%). Point mutations impair GTPase activity, locking RAS in active GTP-bound state → continuous proliferative signaling. Activated in lung, colon, pancreatic carcinomas (KRAS)
- BRAF (V600E): mutation activates MAPK pathway; found in ~60% of melanomas, papillary thyroid carcinoma; targetable with vemurafenib
Nonreceptor Tyrosine Kinases
- BCR-ABL fusion: translocation t(9;22) - Philadelphia chromosome in CML - constitutively active ABL kinase; targeted by imatinib
- JAK2 V617F: myeloid neoplasms (polycythemia vera); relieves cells of erythropoietin dependence; targeted by ruxolitinib
Transcription Factors
- All signal transduction pathways converge on nuclear transcription factors
- MYC: most commonly dysregulated transcription factor in cancer; promotes:
- D cyclin expression → cell cycle progression
- Ribosomal RNA synthesis → protein synthesis capacity
- Metabolic reprogramming (Warburg effect)
- Telomerase expression → immortality
- Stem cell reprogramming
- Burkitt lymphoma: virtually always has MYC translocation t(8;14)
Mechanisms of Proto-oncogene Activation:
| Mechanism | Example |
|---|
| Point mutation | RAS in colon/lung/pancreatic cancer |
| Gene amplification | HER2 in breast cancer; N-MYC in neuroblastoma |
| Chromosomal translocation (promoter substitution) | MYC in Burkitt lymphoma (t[8;14]) |
| Chromosomal translocation (fusion protein) | BCR-ABL in CML (Philadelphia chromosome t[9;22]) |
Hallmark 2: Insensitivity to Growth Inhibition - Tumor Suppressor Genes
Tumor suppressors encode proteins that oppose the hallmarks of cancer. Their mutations are typically loss-of-function and recessive (both alleles must be lost for transformation - the two-hit hypothesis).
Exception: Haploinsufficiency - in some genes, loss of just one allele is sufficient because normal function requires two doses.
RB: Master Regulator of the Cell Cycle
The retinoblastoma protein (RB) is the central governor of the G1/S checkpoint.
- In quiescent cells: RB is hypophosphorylated and binds/inhibits E2F transcription factors, blocking S-phase entry
- With growth signals: cyclin D-CDK4/6 phosphorylates RB → releases E2F → cell enters S phase
- Cancer disrupts this via: RB mutation (retinoblastoma, osteosarcoma), CDK4 amplification, cyclin D overexpression, p16INK4a loss
- Viral oncoproteins (HPV E7, adenovirus E1A, SV40 large T antigen) bind and inactivate RB
- RB is functionally disabled in virtually all human cancers through one mechanism or another
TP53: Guardian of the Genome
p53 is the most frequently mutated gene in human cancer (biallelic loss-of-function in most cancers); germline mutations cause Li-Fraumeni syndrome.
p53 acts as a sensor for diverse cellular stresses:
- DNA damage
- Oncogene activation
- Hypoxia
- Nucleotide depletion
p53 response:
- Normally p53 is kept low by MDM2 (E3 ubiquitin ligase that promotes p53 degradation)
- Stress signals (ATM/ATR kinases) phosphorylate p53 → releases from MDM2 → p53 stabilizes
- Active p53 upregulates:
- p21 (CDK inhibitor) → G1/S arrest → time for DNA repair
- GADD45 → DNA repair
- BAX → apoptosis
- Senescence programs if damage is irreparable
- Inactivated by HPV E6 protein (accelerates p53 degradation)
APC: Gatekeeper of Colonic Neoplasia
APC is the Wnt pathway brake. Germline loss causes familial adenomatous polyposis (FAP); somatic loss in 70-80% of sporadic colorectal cancers.
- APC protein forms a "destruction complex" (with Axin and GSK-3β) that phosphorylates β-catenin for proteasomal degradation
- Loss of APC → β-catenin accumulates → translocates to nucleus → forms TCF complex → activates MYC, cyclin D1, and other progrowth genes
- Tumors with normal APC often instead have activating β-catenin mutations
Other Key Tumor Suppressors:
| Gene | Protein | Function | Familial Syndrome |
|---|
| PTEN | PTEN phosphatase | Inhibits PI3K/AKT signaling | Cowden syndrome |
| VHL | VHL protein | Inhibits HIF-1α (hypoxia-induced transcription) | VHL syndrome, renal cell carcinoma |
| CDKN2A | p16INK4a / p14ARF | CDK inhibitor / p53 stabilizer | Familial melanoma |
| SMAD2/4 | SMAD proteins | TGF-β signaling (growth inhibitory) | Colorectal, pancreatic carcinoma |
| NF1 | Neurofibromin-1 | Inhibitor of RAS/MAPK signaling | Neurofibromatosis type 1 |
| BRCA1/2 | BRCA proteins | DNA repair (homologous recombination) | Familial breast/ovarian cancer |
Hallmark 3: Evasion of Apoptosis
Cancer cells resist programmed cell death through:
- BCL2 overexpression: t(14;18) translocation in follicular lymphoma places BCL2 under Ig heavy chain promoter → BCL2 overexpressed → blocks cytochrome c release from mitochondria → apoptosis blocked
- Loss of BAX (pro-apoptotic)
- Loss of p53 (major inducer of apoptosis)
- Anoikis resistance: tumor cells resist apoptosis triggered by loss of matrix attachment (mediated by altered integrin expression)
Hallmark 4: Limitless Replicative Potential (Immortality)
Three interrelated factors:
1. Evasion of Senescence
- Normal cells divide 60-70 times then permanently exit the cell cycle (senescence)
- Senescence driven by p53 and p16/INK4a maintaining RB hypophosphorylated
- Cancer cells bypass senescence via RB/p53 pathway disruption
2. Evasion of Mitotic Crisis
- Cells that bypass senescence still die via progressive telomere shortening
- When telomeres are eroded: exposed chromosome ends trigger DNA damage response → if p53 is intact, apoptosis; if p53 is lost, breakage-fusion-bridge cycles cause catastrophic genomic damage
- Cancer cells that survive crisis must reactivate telomerase
- 85-95% of tumors express telomerase; remainder use alternative lengthening of telomeres (ALT) via DNA recombination
3. Self-Renewal (Cancer Stem Cells)
- Tissue stem cells naturally express telomerase and have self-renewal capacity
- Cancer may arise from stem cells or from differentiated cells that acquire stem-like properties
- Cancer stem cells are the source of tumor recurrence and therapy resistance
Hallmark 5: Altered Cellular Metabolism - Warburg Effect
Even in ample oxygen, cancer cells preferentially use aerobic glycolysis (glucose → lactate via glycolysis rather than oxidative phosphorylation). This is the Warburg effect (Nobel Prize 1931).
Why glycolysis over oxidative phosphorylation?
- Oxidative phosphorylation converts glucose entirely to CO₂ + H₂O → no carbon available for biosynthesis
- Aerobic glycolysis provides carbon intermediates for synthesis of DNA, proteins, lipids, and organelles needed for cell division
- Glutamine also provides carbon via the TCA cycle for lipid biosynthesis (citrate → acetyl-CoA)
Clinical relevance: This "glucose hunger" is exploited by PET scanning with ¹⁸F-fluorodeoxyglucose (FDG)
Oncometabolites: Mutations in IDH1/IDH2 produce 2-hydroxyglutarate, which inhibits DNA demethylation enzymes (TET2) and histone demethylases → epigenetic silencing of differentiation genes → blocks maturation
Hallmark 6: Sustained Angiogenesis
Tumor cells must induce new vessel formation (angiogenesis) to grow beyond ~1-2 mm:
- VEGF (Vascular Endothelial Growth Factor) is the dominant pro-angiogenic factor
- Upregulated by HIF-1α in hypoxia, by RAS/MYC oncogenes, and released from ECM by MMPs
- VHL tumor suppressor normally targets HIF-1α for degradation - loss of VHL (renal cell carcinoma) → constitutive HIF-1α → VEGF overproduction
- Anti-VEGF therapy (bevacizumab) is approved for multiple cancers
Hallmark 7: Invasion and Metastasis
Steps in tumor invasion:
- Reduced cell-cell adhesion - loss of E-cadherin (tumor suppressor function); gain of N-cadherin (mesenchymal marker) = Epithelial-Mesenchymal Transition (EMT)
- ECM degradation - upregulation of matrix metalloproteinases (MMPs), especially MMP2 and MMP9, which cleave collagen IV and laminin in basement membranes; MMP cleavage products also release VEGF and create new integrin-binding sites
- Altered integrin expression - cancer cells change integrin repertoire to facilitate migration along degraded ECM; resistance to anoikis (loss of normal matrix survival signals)
- Locomotion - driven by autocrine motility factors (chemokines, IGF), matrix cleavage products, stromal cell paracrine factors (HGF/scatter factor acting via MET receptor)
- Intravasation → systemic circulation → extravasation → colonization at distant site (organ tropism governed by chemokine receptor-ligand pairs and pre-metastatic niche)
Hallmark 8: Evasion of Host Immune Response
Tumors escape immune destruction via:
- Loss of MHC-I expression → invisible to CD8+ cytotoxic T cells
- Loss of tumor antigens → no target for immune recognition
- PD-L1/PD-L2 upregulation → engage PD-1 on T cells → T cell exhaustion/inhibition
- CTLA-4 promotion → neutralizes B7 on APCs → reduces T cell activation
- Immunosuppressive cytokines: TGF-β, IL-10, prostaglandin E2, VEGF (blocks T cell trafficking into tumor)
- Regulatory T cell (Treg) induction → active immune suppression in tumor microenvironment
- Myeloid-derived suppressor cells (MDSCs) in tumor microenvironment
Therapeutic implication: Immune checkpoint blockade (anti-CTLA-4, anti-PD-1/PD-L1 antibodies) removes these brakes and can achieve durable remissions and possible cures by restoring tumor-specific T cell memory.
Enabling Characteristic: Genomic Instability
Genomic instability accelerates acquisition of all cancer hallmarks by increasing mutation rate (mutator phenotype):
DNA Repair Gene Defects:
| Pathway | Syndrome | Cancer Risk |
|---|
| Mismatch repair (MMR) | HNPCC/Lynch syndrome | Colorectal carcinoma; microsatellite instability (MSI) |
| Nucleotide excision repair (NER) | Xeroderma pigmentosum | UV-induced skin cancers; can't repair pyrimidine dimers |
| Homologous recombination | BRCA1/2 mutations, Bloom syndrome, Ataxia-telangiectasia, Fanconi anemia | Breast, ovarian, and other carcinomas |
| DNA polymerase proofreading | POLE/POLD1 mutations | Colorectal and endometrial carcinoma |
Chromosomal Changes:
- Translocations activate oncogenes by:
- Promoter/enhancer substitution (e.g., MYC brought under Ig promoter in Burkitt lymphoma)
- Fusion proteins with novel activity (e.g., BCR-ABL in CML)
- Amplifications create extra copies of oncogenes (shown as double minutes or homogeneously staining regions on karyotype)
- Deletions remove tumor suppressor genes
- Whole chromosome gains/losses (aneuploidy)
Enabling Characteristic: Epigenetic Alterations
Beyond DNA sequence changes, epigenetic mechanisms drive carcinogenesis:
- DNA hypermethylation of CpG islands in promoters of tumor suppressor genes silences them without mutation
- Global DNA hypomethylation activates proto-oncogenes and promotes genomic instability
- Histone modifications (methylation, acetylation) alter chromatin accessibility
- MicroRNAs - can act as oncogenes (oncomirs) by silencing tumor suppressors, or as tumor suppressors by silencing oncogenes
Multistep Carcinogenesis: Putting It All Together
Colorectal carcinoma is the classic model of stepwise molecular carcinogenesis:
Normal epithelium → Adenoma → Carcinoma
- APC loss (or β-catenin mutation) - initiating event; activates Wnt/MYC/cyclin D1
- KRAS mutation - drives autonomous proliferation
- SMAD4 loss - disables TGF-β growth inhibition
- TP53 loss - eliminates apoptosis/senescence checkpoint
- Additional driver mutations → invasion and metastasis
This model illustrates that no single mutation is sufficient - cancer requires accumulation of complementary mutations in multiple gene classes over time.
Robbins, Cotran & Kumar - Pathologic Basis of Disease (ISBN 9780443264528), Chapter 7, pp. 247-307